Table 2 Characteristics and major findings of included studies
Authors | Years | Targeting point or drugs | Major findings |
|---|---|---|---|
Li [35] | 2011 | Notch pathway | Inhibition pf Notch signaling with the γ-secretase inhibitor DAPT inhibits OCSCs from self-renewing and proliferating |
Shannon [32] | 2012 | Notch pathway | Notch3 siRNA knockdown depletes OCSCs and increases tumor sensitivity to platinum |
Sham [36] | 2014 | Notch pathway | Withaferin A used alone or in combination with cisplatin targets putative OCSCs |
Hyeok [37] | 2016 | Notch pathway | Galectin-3 maintains OCSCs by activating the Notch1 intracellular domain |
Eun [129] | 2016 | Notch pathway | Hypoxia-Notch-SOX2 signaling axis is vital for activation of OCSCs |
Zhu [130] | 2019 | Notch 1-c-Myc pathway | SNORD89 regulates Notch 1-c-Myc pathway to promote cell stemness and acts as an oncogene in ovarian tumorigenesis |
Zhang [131] | 2020 | Notch 1-c-Myc pathway | Stemness transformation of OC cells can be activated by SNORA72 through the Notch 1-c-Myc pathway |
Chau [43] | 2013 | Wnt/β-catenin pathway | The activation of Wnt/β-catenin and ATP-binding cassette G2 downstream of c-Kit could promote OCSCs |
Mariya [132] | 2016 | Wnt/β-catenin pathway | MMP10 activate canonical Wnt signaling by inhibiting noncanonical Wnt signaling ligand Wnt5a |
Chen [133] | 2017 | Wnt/β-catenin pathway | STAT3 signaling maintained stemness and interconnected Wnt/β-catenin signaling via the miR-92a/DKK1 regulatory pathways |
Deng [45] | 2017 | Wnt/β-catenin pathway | Rb1 and compound K can chemosensitize OCSCs, inducing a synergistic cytotoxicity via Wnt/β-catenin pathway and epithelial-to-mesenchymal (EMT) transition regulation |
Wen [114] | 2017 | Wnt/β-catenin pathway | SOX2 may directly bind to bcatenin and activate the Wnt/β-catenin pathway to maintain the stemness of ovarian spheroids |
Srivastava [46] | 2018 | Wnt/β-catenin pathway | Calcitriol is able to deplete the OCSC population by inhibiting their Wnt signaling Pathway |
Wu [134] | 2015 | Wnt/β-catenin pathway | MiR-1207 enhances the stem cell-like traits of OC cells by downregulating of multiple negative modulators of the Wnt/β-catenin pathway |
Pan [44] | 2018 | Wnt/β-catenin pathway | Theaflavin-3, 3′-digallate inhibits OCSCs through Wnt/β-catenin signaling pathway |
Deng [50] | 2019 | PI3K/Akt/mTOR pathway | EMT and enhanced CSC marker expression triggered by activated PI3K/Akt/mTOR signaling are involved in the chemoresistance of EOC |
2016 | PI3K/Akt/mTOR pathway | The reduced OVCSLC oncogenicity by DFOG through inhibitory effects on AKT and/or ERK and/or NF-κB pathways requires both FoxO3a and FoxM1 expression | |
Leizer [52] | 2010 | NF-κB pathway | EriB can inhibit NF-κB activity by down-regulating the level of nuclear p65 |
Jiang [52] | 2022 | NF-κB pathway | PFKFB3 is a key process of glycolysis in OCSCs and its inhibitor can impede stem properties |
Xia [52] | 2014 | Hippo pathway | The self-renewal and chemoresistance properties of OCSCs depend on YAP and TEADs |
Feng [52] | 2016 | Hippo pathway | VP can increase YAP expression, resulting in the suppression of OCSCs progression |
Casagrande [71] | 2011 | CD44 | Intraperitoneal CPE administration could eradicate CD44 + OCSCs after conventional therapy |
Cheng [72] | 2011 | CD44 | MiR-199a targets CD44 and reduces the proliferation and invasion of CD44 +/CD117 + ovarian cancer stem cells in vitro and in vivo |
Wu [135] | 2015 | CD44 | Human SKOV3 CD117 + CD44 + CSC-based vaccine may induce the anti-OCimmunity against tumor growth by reducing the CD117 + CD44 + CSC population |
Skubitz [78] | 2013 | CD133 | dCD133KDEL is a novel deimmunized toxin that appears to be targeting and eliminating CD133 + tumor initiating cells |
Xiang [80] | 2013 | CD133 | The stimulation function of IL-17 on self-renewal of CD133 + OCSCs might be mediated by NF-kB and MAPK signaling pathway |
Wang [81] | 2016 | CD133 | IL-23 contribute to ovarian cancer malignancy through promoting the self-renewal of CD133 + ovarian cancer stem-like cells |
Long [79] | 2016 | CD133 | The Cre/LoxP system-mediated tBid overexpression activated the pro-apoptotic signaling pathway and augmented the cytotoxic effect of cisplatin in CD133 + OCSCs |
Kim [91] | 2018 | ALDH | ATRA suppressed ALDH1 expression, inhibiting NRF2 activation, which led to the attenuation of CSC-like properties in ALDH-H cells but not in ALDH-L cells |
Choi [96] | 2015 | ALDH | BMP2 promotes the expansion of ALDH + C133 + OCSCs and restricting the growth of progenitor |
Kakar [94] | 2017 | ALDH | WFA alone or when combined with CIS resulted in a significant suppression of tumorigenic function of isolated ALDH1 positive cancer stem cells in vitro |
Young [92] | 2014 | ALDH | ATRA downregulates ALDH1/FoxM1/Notch1 signaling and suppresses tumor formation in OC cells |
Cui [93] | 2018 | ALDH | DDB2, a transcription repressor, can abrogate ovarian CSC properties by downregulating ALDH1A1 expression |
Shank [103] | 2012 | Metformin | Metformin can restrict the growth and proliferation of ovarian cancer stem cells in vitro and in vivo |
Zhang [106] | 2015 | Metformin | Metformin at low dose inhibits selectively CD44 + CD117 + OCSCs through inhibition of EMT and potentiates the effect of cisplatin |
Lee [115] | 2017 | Salinomycin | Combining salinomycin with other anti-cancer therapeutic agents can target OCSCs |
Mi [116] | 2017 | Salinomycin | Salinomycin-loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies can eliminate CD133 + OCSCs |
Lee [123] | 2020 | Calcium channel blockers | Combination CCBs with cisplatni can inhibit the viability and proliferation of OCSCs |
Lee [124] | 2020 | Calcium channel blockers | Poziotinib with a CCB can effectively inhibit OCSC survival and function |